EMBRACE: Phase 3/4, Randomized, 52 ‐Week Study of Belimumab Efficacy and Safety in Patients of Black African Ancestry With Systemic Lupus Erythematosus

ConclusionsThe primary endpoint of this study was not achieved, but improvement with belimumab versus placebo was observed, suggesting that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry.

https://onlinelibrary.wiley.com/doi/10.1002/art.41900?af=R

Source: Arthritis and Rheumatology - June 24, 2021 Category: Rheumatology Authors: Ellen Ginzler, Luiz Sergio Guedes Barbosa, David D ’Cruz, Richard Furie, Kathleen Maksimowicz‐McKinnon, James Oates, Mittermayer Barreto Santiago, Amit Saxena, Saira Sheikh, Damon L. Bass, Susan W. Burriss, Jennifer A. Gilbride, James G. G Tags: FULL LENGTH Source Type: research